Zoetis ZTS
NYSE ZTS
$84.39 +0.57 (+0.68%)
At close: Nov 16, 2026 · 4:00 PM EST

Zoetis (ZTS) Net Income towards Common Stockholders (2012 - 2026)

Updated

Zoetis (ZTS) posted Net Income towards Common Stockholders of $591 million for Q3 2026, down 18.0% from $721 million a year earlier and down 14.5% from the prior quarter.

Analysis

Zoetis (ZTS) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Net Income towards Common Stockholders at Zoetis was $2.51 billion, down 4.7% year-over-year; for FY2025, it came in at $2.67 billion, up 7.5% from FY2024.

  • Annual Net Income towards Common Stockholders has increased for ten consecutive years, with a five-year compound annual growth rate of 10.3% (FY2020 to FY2025).
  • In prior years, Zoetis' Net Income towards Common Stockholders was $2.49 billion in FY2024 (+6.1%), $2.34 billion in FY2023 (+10.9%), $2.11 billion in FY2022 (+3.8%) and $2.04 billion in FY2021 (+24.4%).
  • The Q3 2026 figure stands as the lowest quarterly Net Income towards Common Stockholders since Q4 2024.
  • On a year-over-year basis, Net Income towards Common Stockholders has declined in each of the last three quarters, with growth averaging 2.2% over the last eight quarters.
  • The strongest year-over-year quarter for Net Income towards Common Stockholders in the past five years was Q2 2023, with growth of 26.8%; the weakest was Q3 2026, with a decline of 18.0%.
  • According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was $691 million (Q2 2026), $601 million (Q1 2026) and $624 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 210.00 Mn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 4.22 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 3.12 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 2.43 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 3.24 Bn
10 Zoetis 34.65 Bn 27.05 Bn 1.69 Bn 591.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 591.00 Mn
Jun 30, 2026 691.00 Mn
Mar 31, 2026 601.00 Mn
Dec 31, 2025 624.00 Mn
Sep 30, 2025 721.00 Mn
Jun 30, 2025 726.00 Mn
Mar 31, 2025 602.00 Mn
Dec 31, 2024 581.00 Mn
Sep 30, 2024 682.00 Mn
Jun 30, 2024 624.00 Mn
Mar 31, 2024 599.00 Mn
Dec 31, 2023 525.00 Mn
Sep 30, 2023 596.00 Mn
Jun 30, 2023 671.00 Mn
Mar 31, 2023 552.00 Mn
Dec 31, 2022 461.00 Mn
Sep 30, 2022 529.00 Mn
Jun 30, 2022 529.00 Mn
Mar 31, 2022 595.00 Mn
Dec 31, 2021 414.00 Mn
API Access

Zoetis Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ZTS&period=max&api_key=YOUR_API_KEY